New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:27 EDTALNY, KWR, GSVC, FARO, ETM, EPAM, EGHT, CASH, BMTC, AME, CUBIEmerald Advisers to hold a forum
21st Groundhog Day Investment Forum is being held in Philadelphia on Feburary 6.
News For ALNY;AME;BMTC;CASH;EGHT;EPAM;ETM;FARO;GSVC;KWR;CUBI From The Last 14 Days
Check below for free stories on ALNY;AME;BMTC;CASH;EGHT;EPAM;ETM;FARO;GSVC;KWR;CUBI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:58 EDTFAROBrean Capital to hold a conference
Subscribe for More Information
August 27, 2014
08:15 EDTEGHT8x8, Inc. issued new communications patent by USPTO
Subscribe for More Information
08:02 EDTALNYAlnylam receives notice of allowance from USPTO for new patent
Subscribe for More Information
August 21, 2014
16:35 EDTBMTCBryn Mawr Bank acquires Craft Parker & Beard
Subscribe for More Information
14:57 EDTFAROFARO Technologies management to meet with Stephens
Meeting with management to be held in the Mid-Atlantic area on August 26-27 hosted by Stephens.
09:16 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 20, 2014
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
August 19, 2014
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
10:13 EDTFAROOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:34 EDTFAROFARO Technologies initiated with an Overweight at Stephens
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use